1. Home
  2. CRBP vs CRT Comparison

CRBP vs CRT Comparison

Compare CRBP & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • CRT
  • Stock Information
  • Founded
  • CRBP 2009
  • CRT 1991
  • Country
  • CRBP United States
  • CRT United States
  • Employees
  • CRBP N/A
  • CRT N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • CRBP Health Care
  • CRT Energy
  • Exchange
  • CRBP Nasdaq
  • CRT Nasdaq
  • Market Cap
  • CRBP 73.4M
  • CRT 65.1M
  • IPO Year
  • CRBP N/A
  • CRT 1992
  • Fundamental
  • Price
  • CRBP $8.33
  • CRT $9.79
  • Analyst Decision
  • CRBP Strong Buy
  • CRT
  • Analyst Count
  • CRBP 10
  • CRT 0
  • Target Price
  • CRBP $53.56
  • CRT N/A
  • AVG Volume (30 Days)
  • CRBP 123.5K
  • CRT 26.8K
  • Earning Date
  • CRBP 08-05-2025
  • CRT 01-01-0001
  • Dividend Yield
  • CRBP N/A
  • CRT 9.32%
  • EPS Growth
  • CRBP N/A
  • CRT N/A
  • EPS
  • CRBP N/A
  • CRT 0.99
  • Revenue
  • CRBP N/A
  • CRT $6,834,116.00
  • Revenue This Year
  • CRBP N/A
  • CRT N/A
  • Revenue Next Year
  • CRBP $150.03
  • CRT N/A
  • P/E Ratio
  • CRBP N/A
  • CRT $9.85
  • Revenue Growth
  • CRBP N/A
  • CRT N/A
  • 52 Week Low
  • CRBP $4.64
  • CRT $8.88
  • 52 Week High
  • CRBP $61.90
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 54.09
  • CRT 44.17
  • Support Level
  • CRBP $8.10
  • CRT $9.95
  • Resistance Level
  • CRBP $9.45
  • CRT $10.38
  • Average True Range (ATR)
  • CRBP 0.52
  • CRT 0.25
  • MACD
  • CRBP -0.08
  • CRT 0.03
  • Stochastic Oscillator
  • CRBP 55.74
  • CRT 45.38

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: